Riboflavin Transporters RFVT/SLC52A Mediate Translocation of Riboflavin, Rather than FMN or FAD, across Plasma Membrane
-
- Jin Congyun
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Yao Yoshiaki
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Yonezawa Atsushi
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Imai Satoshi
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Yoshimatsu Hiroki
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Otani Yuki
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Omura Tomohiro
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Nakagawa Shunsaku
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Nakagawa Takayuki
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
-
- Matsubara Kazuo
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
この論文をさがす
説明
<p>Riboflavin (vitamin B2) plays a role in various biochemical oxidation-reduction reactions. Flavin mononucleotide (FMN) and FAD, the biologically active forms, are made from riboflavin. Riboflavin transporters (RFVTs), RFVT1-3/Slc52a1-3, have been identified. However, the roles of human (h)RFVTs in FMN and FAD homeostasis have not yet been fully clarified. In this study, we assessed the contribution of each hRFVT to riboflavin, FMN and FAD uptake and efflux using in vitro studies. The transfection of hRFVTs increased cellular riboflavin concentrations. The uptake of riboflavin by human embryonic kidney cells transfected with hRFVTs was significantly increased, and the efflux was accelerated in a time-dependent manner. However, the uptake and efflux of FMN and FAD hardly changed. These results strongly suggest that riboflavin, rather than FMN or FAD, passes through plasma membranes via hRFVTs. Our findings could suggest that hRFVTs are involved in riboflavin homeostasis in the cells, and that FMN and FAD concentrations are regulated by riboflavin kinase and FAD synthase.</p>
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 40 (11), 1990-1995, 2017
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679610687744
-
- NII論文ID
- 130006191824
-
- NII書誌ID
- AA10885497
-
- ISSN
- 13475215
- 09186158
-
- HANDLE
- 2433/276093
-
- NDL書誌ID
- 028602406
-
- PubMed
- 29093349
-
- 本文言語コード
- en
-
- 資料種別
- journal article
-
- データソース種別
-
- JaLC
- IRDB
- NDLサーチ
- Crossref
- PubMed
- CiNii Articles
- KAKEN
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可